Table 1.
Baseline characteristics by diagnosis period
| Weeks 2–8 | Weeks 9–11 | Weeks 12–13 | Weeks 14–17 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018/2019a | 2020 | p | 2018/2019a | 2020 | p | 2018/2019a | 2020 | p | 2018/2019a | 2020 | p | |
| Patients | 2547.5 | 2692 | 1074.5 | 995 | 737.5 | 436 | 1402 | 646 | ||||
| Age | ||||||||||||
| < 40 | 129.5 (5.1) | 142 (5.3) | 0.02 | 51 (4.8) | 44 (4.4) | 0.55 | 36.5 (5.0) | 19 (4.4) | 0.42 | 54 (3.9) | 64 (9.9) | < 0.01 |
| 40–49 | 389.5 (15.3) | 372 (13.8) | 158.5 (14.8) | 128 (12.9) | 104.5 (14.2) | 62 (14.2) | 204.5 (14.6) | 111 (17.2) | ||||
| 50–64 | 912.5 (35.8) | 898 (33.4) | 387.5 (36.1) | 368 (37.0) | 266.5 (36.1) | 175 (40.1) | 524.5 (37.4) | 200 (31.0) | ||||
| 65–74 | 674 (26.5) | 771 (28.6) | 284.5 (26.5) | 282 (28.3) | 206.5 (28.0) | 121 (27.8) | 358 (25.5) | 118 (18.3) | ||||
| > 74 | 442 (17.4) | 509 (18.9) | 193 (18.0) | 173 (17.4) | 123.5 (16.8) | 59 (13.5) | 261 (18.6) | 153 (23.7) | ||||
| SES | ||||||||||||
| High | 782.5 (30.7) | 788 (29.3) | < 0.01 | 295.5 (27.5) | 316 (31.8) | 0.04 | 211.5 (28.7) | 133 (30.5) | 0.47 | 410.5 (29.3) | 206 (31.9) | 0.28 |
| Medium | 992.5 (39.0) | 1169 (43.4) | 421 (39.2) | 379 (38.1) | 282.5 (38.3) | 153 (35.1) | 569.5 (40.6) | 242 (37.5) | ||||
| Low | 763.5 (30.0) | 719 (26.7) | 355 (33.0) | 298 (30.0) | 239.5 (32.5) | 148 (33.9) | 413.5 (29.5) | 193 (29.9) | ||||
| Unknown | 9 (0.4) | 16 (0.6) | 3 (0.3) | 2 (0.2) | 4 (0.5) | 2 (0.5) | 8.5 (0.6) | 5 (0.8) | ||||
| Morphology | ||||||||||||
| DCIS | 309 (12.1) | 352 (13.1) | 0.44 | 119.5 (11.1) | 125 (12.6) | 0.33 | 79.5 (10.8) | 65 (14.9) | 0.03 | 178 (12.7) | 42 (6.5) | 0.00 |
| Invasive ductal | 1761.5 ( 69.2) | 1828 (67.9) | 756 (70.4) | 671 (67.4) | 504.5 (68.4) | 294 (67.4) | 951 (67.8) | 480 (74.3) | ||||
| Invasive lobular | 342.5 (13.4) | 380 (14.1) | 135 (12.6) | 141 (14.2) | 122 (16.5) | 55 (12.6) | 198 (14.1) | 92 (14.2) | ||||
| Other | 134.5 (5.3) | 132 (4.9) | 64 (6.0) | 58 (5.8) | 31.5 (4.3) | 22 (5.1) | 75 (5.4) | 32 (5.0) | ||||
| Stage | ||||||||||||
| DCIS | 309 (12.2) | 352 (13.2) | 0.25 | 119.5 (11.1) | 125 (12.6) | 0.69 | 79.5 (10.8) | 65 (15.0) | 0.09 | 178 (12.7) | 42 (6.6) | < 0.01 |
| Stage I | 1044.5 (41.1) | 1075 (40.4) | 446 (41.6) | 418 (42.2) | 306 (41.6) | 167 (38.6) | 559.5 (40.0) | 212 (33.1) | ||||
| Stage II | 828.5 (32.6) | 891 (33.5) | 358 (33.4) | 316 (31.9) | 247 (33.6) | 142 (32.8) | 473.5 (33.8) | 269 (42.0) | ||||
| Stage III | 233.5 (9.2) | 211 (7.9) | 97 (9.0) | 82 (8.3) | 72 (9.8) | 35 (8.1) | 122 (8.7) | 64 (10.0) | ||||
| Stage IV | 128 (5.0) | 134 (5.0) | 52 (4.9) | 49 (5.0) | 31 (4.2) | 24 (5.5) | 66.5 (4.8) | 54 (8.4) | ||||
| Subtype | ||||||||||||
| HR+/HER2+ | 210 (8.2) | 171 (6.4) | 0.01 | 74.5 (6.9) | 64 (6.4) | 0.88 | 48.5 (6.6) | 30 (6.9) | 0.59 | 111.5 (8.0) | 62 (9.6) | 0.12 |
| HR+/HER2– | 1678 (65.9) | 1743 (64.8) | 717 (66.7) | 657 (66.0) | 510 (69.2) | 286 (65.6) | 921.5 (65.7) | 428 (66.3) | ||||
| HR−/HER2+ | 83 (3.3) | 65 (2.4) | 41.5 (3.9) | 33 (3.3) | 30 (4.1) | 11 (2.5) | 42 (3.0) | 30 (4.6) | ||||
| HR−/HER2− | 249 (9.8) | 275 (10.2) | 112 (10.4) | 98 (9.9) | 64.5 (8.8) | 35 (8.0) | 137.5 (9.8) | 76 (11.8) | ||||
| Unknown | 327.5 (12.9) | 438 (16.3) | 129.5 (12.1) | 143 (14.4) | 84.5 (11.5) | 74 (17.0) | 189.5 (13.5) | 50 (7.7) | ||||
| Region | ||||||||||||
| North | 257.5 (10.1) | 254 (9.4) | 0.02 | 111.5 (10.4) | 99 (10.0) | 0.74 | 74 (10.0) | 46 (10.6) | 0.17 | 135 (9.6) | 71 (11.0) | 0.86 |
| Middle East | 230.5 (9.1) | 257 (9.6) | 98.5 (9.2) | 97 (9.8) | 71.5 (9.7) | 55 (12.6) | 123.5 (8.8) | 59 (9.1) | ||||
| Middle | 488 (19.2) | 589 (21.9) | 214 (19.9) | 208 (20.9) | 139 (18.9) | 94 (21.6) | 297.5 (21.2) | 132 (20.4) | ||||
| West | 1010.5 (39.7) | 991 (36.8) | 406 (37.8) | 384 (38.6) | 304.5 (41.3) | 165 (37.8) | 538 (38.4) | 246 (38.1) | ||||
| South | 560.5 (22.0) | 600 (22.3) | 244.5 (22.8) | 207 (20.8) | 148.5 (20.1) | 76 (17.4) | 308 (22.0) | 138 (21.4) | ||||
| Screened | ||||||||||||
| Yes | 810 (31.8) | 837 (31.1) | 0.87 | 354.5 (33.0) | 342 (34.4) | 0.43 | 256.5 (34.8) | 172 (39.5) | 0.12 | 455.5 (32.5) | 12 (1.9) | 0.00 |
| No | 727.5 (28.6) | 762 (28.3) | 299 (27.8) | 275 (27.6) | 201.5 (27.3) | 107 (24.5) | 403.5 (28.8) | 282 (43.7) | ||||
| Not eligible | 961 (37.7) | 1023 (38.0) | 402.5 (37.5) | 345 (34.7) | 264.5 (35.9) | 140 (32.1) | 519.5 (37.1) | 328 (50.8) | ||||
| Unknown | 49 (1.9) | 70 (2.6) | 18.5 (1.7) | 33 (3.3) | 15 (2.0) | 17 (3.9) | 23.5 (1.7) | 24 (3.7) | ||||
Data are reported as N (%) of patients diagnosed in weeks 2–17 of 2018/2019 or 2020
The p value was calculated on known values only, using the chi-square test to compare patients diagnosed in weeks 2–8, 9–11, 12–13, or 14–17 of 2020 with those diagnosed in the same period from the average for the years 2018 and 2019
DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; SES, socioeconomic status
aThe average was taken over 2018 and 2019